scholarly journals Short-Term Lung Function Changes and Predictors of Progressive Systemic Sclerosis–Related Interstitial Lung Disease

2020 ◽  
Vol 83 (4) ◽  
pp. 312-320
Author(s):  
Punchalee Kaenmuang ◽  
Asma Navasakulpong
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Function ◽  
Lung Disease ◽  
Progressive Systemic Sclerosis ◽  
Short Term

scholarly journals P33 Rituximab as rescue therapy in advanced progressive systemic sclerosis associated interstitial lung disease

Thorax ◽  
2015 ◽  
Vol 70 (Suppl 3) ◽  
pp. A92.2-A92
Author(s):  
M Kokosi ◽  
P Saunders ◽  
K Karagiannis ◽  
F Chua ◽  
TM Maher ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Rescue Therapy ◽  
Progressive Systemic Sclerosis

scholarly journals Impact of Lung Function Decline on Time to Hospitalisation Events in Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD): a Joint Model Analysis

2021 ◽  
Author(s):  
Michael Kreuter ◽  
Francesco Del Galdo ◽  
Corinna Miede ◽  
Dinesh Khanna ◽  
Wim A. Wuyts ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Function ◽  
Lung Disease ◽  
Fold Increase ◽  
Phase Iii ◽  
Lung Function Decline ◽  
Related Hospitalisation ◽  
The Relationship ◽  
Increase In Risk

Abstract Background: Interstitial lung disease (ILD) is a common organ manifestation in systemic sclerosis (SSc) and is the leading cause of death in patients with SSc. A decline in forced vital capacity (FVC) is an indicator of ILD progression and is associated with mortality in patients with SSc-associated ILD (SSc-ILD). However, the relationship between FVC decline and hospitalisation events in patients with SSc-ILD is largely unknown. The objective of this post-hoc analysis was to investigate the relationship between FVC decline and clinically important hospitalisation endpoints.Methods: We used data from SENSCIS®, a Phase III trial investigating the efficacy and safety of nintedanib in patients with SSc-ILD. Joint models for longitudinal and time-to-event data were used to assess the association between rate of decline in FVC% predicted and hospitalisation-related endpoints (including time to first all-cause hospitalisation or death; time to first SSc-related hospitalisation or death; and time to first admission to an emergency room [ER] or admission to hospital followed by admission to intensive care unit [ICU] or death) during the treatment period, over 52 weeks in patients with SSc-ILD.Results: There was a statistically significant association between FVC decline and the risk of all-cause (n=78) and SSc-related (n=42) hospitalisations or death (both P<0.0001). A decrease of 3% in FVC corresponded to a 1.43-fold increase in risk of all-cause hospitalisation or death (95% confidence interval [CI] 1.24, 1.65) and a 1.48-fold increase in risk of SSc-related hospitalisation or death (95% CI 1.23, 1.77). No statistically significant association was observed between FVC decline and admission to ER or to hospital followed by admission to ICU or death (n=75; P=0.15). The estimated slope difference for nintedanib versus placebo in the longitudinal sub-model was consistent with the primary analysis in SENSCIS®.Conclusions: The association of lung function decline with an increased risk of hospitalisation suggests that slowing FVC decline in patients with SSc-ILD may prevent hospitalisations. Our findings also provide evidence that FVC decline may serve as a surrogate endpoint for clinically relevant hospitalisation-associated endpoints.Trial registration: Clinialtrials.gov, NCT02597933. Registered 8 October 2015, https://clinicaltrials.gov/ct2/show/study/NCT02597933.

scholarly journals Lung Function and Survival in Systemic Sclerosis Interstitial Lung Disease

2014 ◽  
Vol 41 (11) ◽  
pp. 2326-2328 ◽  
Author(s):  
SAMAR SHADLY AHMED ◽  
SINDHU R. JOHNSON ◽  
CHRISTOPHER MEANEY ◽  
CATHY CHAU ◽  
THEODORE K. MARRAS
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Function ◽  
Lung Disease

Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography.

Radiology ◽  
1990 ◽  
Vol 176 (3) ◽  
pp. 755-759 ◽  
Author(s):  
H Schurawitzki ◽  
R Stiglbauer ◽  
W Graninger ◽  
C Herold ◽  
D Pölzleitner ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
High Resolution ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Progressive Systemic Sclerosis ◽  
High Resolution Ct

FRI0254 The Effect of Cyclophosphamide on Lung Function in Different Stages of Interstitial Lung Disease Associated To Systemic Sclerosis: Table 1.

2016 ◽  
Vol 75 (Suppl 2) ◽  
pp. 526.1-526
Author(s):  
W.M.T. Van Den Hombergh ◽  
E. Teesselink ◽  
H.K.A. Knaapen-Hans ◽  
S.O. Simons ◽  
F.H.J. van den Hoogen ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Function ◽  
Lung Disease

scholarly journals Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease

PLoS ONE ◽  
2017 ◽  
Vol 12 (8) ◽  
pp. e0181692 ◽  
Author(s):  
Noémie Le Gouellec ◽  
Alain Duhamel ◽  
Thierry Perez ◽  
Anne-Lise Hachulla ◽  
Vincent Sobanski ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Function ◽  
Lung Disease ◽  
Lung Function Test ◽  
Function Test
Sign in / Sign up

Export Citation Format

Share Document